Article Author:
Reuters
London — European Medicines Agency (EMA) from Pfizer and BioNTech It said Tuesday that it has begun a rolling review of a COVID-19 vaccine adapted for a variant of
The so-called bivalent vaccine targets his two strains of the SARS-CoV-2 virus behind COVID. The original strain, which was first identified in China, and BA.4/5, a derivative of Omicron. Currently, most cases are delayed in Europe.
A rolling review means that EMA will evaluate data as it becomes available, and this process will continue until there is enough data for formal marketing applications. .
Last month, the EMA said it had begun a rolling review of another version of the company's shot, targeting the original his SARS-CoV-2 strain and Omicron's subvariant BA.1. rice field.
Existing coronavirus vaccines continue to provide excellent protection against hospitalizations and deaths, but as the virus evolves, vaccine efficacy has taken a hit.
} European Union officials plan to use a bivalent vaccine in the fall vaccination campaign, and now most cases in the region are associated with the BA.5 variant.
The EMA hopes that a vaccine adapted to the new COVID variant will be approved by September, but given the new BA.4-targeted shots, that campaign will not replace the old BA. .1 variant suggests willingness to use targeted shots. The BA.5 strain is further delayed in clinical development.
You'll get the latest headlines, stories, opinions and photos of Toronto His Sun straight from the newsroom to your inbox at noon.
Thank you for registering.
Sending welcome email. If you don't see it, please check your spam folder.
The next issue of Your Midday Sun will arrive in your mailbox shortly.
